events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Search
Login
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Login
News and Community
Alixorexton
,
Alkermes
,
Healthcare Technology
,
Narcolepsy Treatment
,
Narcolepsy Type 1
,
Orexin 2 Receptor Agonist
,
Ox2r Agonist
August 25, 2026
The Lancet Neurology Publishes Positive Vibrance-1 Phase 2 Data on Alkermes’ Alixorexton in Narcolepsy Type 1
Load More
